---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-028110"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T16:56:22.291389+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcus reports $992M cash; Gilead opts out of casdatifan; ARC-20 data shows ORR 25-33%

## Summary
- Preliminary cash, cash equivalents and marketable securities of $992M as of Dec 31, 2024.
- Gilead's exclusive option for casdatifan expired without exercise; Arcus retains full global rights.
- ARC-20 in ccRCC: 50mg BID median PFS 9.7 months, ORR 25%; 100mg QD ORR 33%.
- Disease control rate 81-87% across cohorts; median DoR not reached; safety acceptable.
- All but two of 26 responders remained on treatment; one discontinuation due to anemia.

## SEC filing metadata
- accession: 0001193125-25-028110
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000119312525028110/0001193125-25-028110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000119312525028110/d901841d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-028110
- JSON: https://secwatch.observer/filing/0001193125-25-028110.json
- Plain text: https://secwatch.observer/filing/0001193125-25-028110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.